SCHEMBL12008740

SCHEMBL12008740

CCc1ccc(/C=C2/SC(=S)N(CCC(=O)O)C2=O)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 2/20 0.83
▸ MAX P61244 2/20 0.83
▸ CISD1 Q9NZ45 2/20 0.76
▸ MAOA P21397 1/20 0.76
▸ MAPT P10636 3/20 0.74
▸ NCOA3 Q9Y6Q9 3/20 0.74
▸ MITF O75030 2/20 0.74
▸ RAB9A P51151 2/20 0.74
▸ ALDH1A1 P00352 3/20 0.73
▸ KMT2A Q03164 8/20 0.72
▸ PSMD14 O00487 2/20 0.72
▸ LMNA P02545 1/20 0.72
▸ SMN1; SMN2 Q16637 1/20 0.72
▸ KDM4E B2RXH2 1/20 0.71
▸ HTT P42858 1/20 0.71
▸ MEN1 O00255 6/20 0.70
▸ TDP1 Q9NUW8 3/20 0.70
▸ BLM P54132 1/20 0.70
▸ SAE1 Q9UBE0 1/20 0.70
▸ UBA2 Q9UBT2 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12008430 0.93 MYC (0.76) MYCMAXCISD1MAOAMAPT
SCHEMBL14905165 0.88 CISD1 (0.79) MYCMAXCISD1MAOAMAPT
SCHEMBL12008748 0.88 CISD1 (0.79) MYCMAXCISD1MAOAMAPT
SCHEMBL10417661 0.88 PTPN12 (0.73) MYCMAXMAPTALDH1A1KMT2A
SCHEMBL10417660 0.88 PTPN12 (0.73) MYCMAXMAPTALDH1A1KMT2A
SCHEMBL15709015 0.86 CISD1 (0.81) CISD1MAOAMAPTNCOA3MITF
SCHEMBL12008711 0.86 CISD1 (0.81) MYCMAXCISD1MAOAMAPT
SCHEMBL18420883 0.86 CISD1 (0.81) CISD1MAOAMAPTNCOA3MITF
SCHEMBL12008493 0.86 CISD1 (0.81) CISD1MAOAMAPTNCOA3MITF
SCHEMBL12008769 0.86 CISD1 (1.00) CISD1MAOAMAPTNCOA3MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 MYC 140/4885MAX 3771/4885CISD1 2475/4885
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof CTNNB1, CTNNA1, CTNNBL1 MYC 93/4885MAX 3628/4885CISD1 2618/4885
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 MYC 93/4885MAX 3628/4885CISD1 2618/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 MYC 93/4885MAX 3628/4885CISD1 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback